What is Nanite?
Founded in 2020, Nanite operates at the intersection of material science and genetic engineering. The company focuses on the development of programmable polymer nanoparticles, which serve as a sophisticated delivery vehicle for genetic payloads. Unlike traditional viral vectors, which can face limitations regarding immunogenicity and manufacturing complexity, Nanite's non-viral approach offers a modular and potentially safer alternative for therapeutic applications. By focusing on the fundamental architecture of delivery systems, Nanite is carving out a distinct niche in the biotechnology sector, aiming to become a foundational partner for pharmaceutical developers seeking to optimize the efficacy of their genetic therapies.
How much funding has Nanite raised?
Nanite has raised a total of $10M across 2 funding rounds:
Angel/Seed
$8M
Angel/Seed
$2M
Angel/Seed (2023): $8M with participation from Cystic Fibrosis Foundation, Zetta Venture Partners, and Arkitekt Ventures
Angel/Seed (2023): $2M led by Cystic Fibrosis Foundation
Key Investors in Nanite
Cystic Fibrosis Foundation
A prominent non-profit organization dedicated to funding research and providing resources to cure cystic fibrosis and improve the quality of life for those affected.
Zetta Venture Partners
A venture capital firm specializing in early-stage AI-native startups, providing strategic capital and operational support to infrastructure and application developers.
Arkitekt Ventures
An early-stage investment fund focused on healthcare delivery models and the application of frontier technologies to enhance human health outcomes.
What's next for Nanite?
With the recent infusion of capital, Nanite is expected to scale its operational capacity and deepen its pipeline of therapeutic candidates. The company's roadmap likely involves expanding its proprietary polymer library and conducting rigorous preclinical validation to demonstrate the versatility of its delivery platform. As the biotechnology industry shifts toward more targeted and efficient gene delivery mechanisms, Nanite's focus on programmable polymers positions it as a key player in the next generation of medical innovation. Future milestones will likely center on strategic partnerships with larger pharmaceutical entities and the transition of its lead programs toward clinical-stage development, ensuring that its technological advancements translate into tangible patient outcomes.
See full Nanite company page
